TASLY PHARMACEUTICAL GROUP CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.63 CNY | +1.36% |
|
-0.64% | -8.17% |
| Sales 2023 | 8.67B 1.2B | Sales 2024 * | 9.94B 1.37B | Capitalization | 23.26B 3.21B |
|---|---|---|---|---|---|
| Net income 2023 | 1.07B 148M | Net income 2024 * | 1.35B 187M | EV / Sales 2023 | 2.72 x |
| Net cash position 2023 | 1.79B 248M | Net cash position 2024 * | 4.35B 601M | EV / Sales 2024 * | 1.9 x |
| P/E ratio 2023 |
23.6
x | P/E ratio 2024 * |
17.4
x | Employees | 9,183 |
| Yield 2023 |
1.94% | Yield 2024 * |
1.43% | Free-Float | 49.13% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +1.36% | ||
| 1 week | -0.64% | ||
| Current month | -2.98% | ||
| 1 month | -8.65% | ||
| 3 months | -4.70% | ||
| 6 months | +9.45% | ||
| Current year | -8.17% |
1 week
15.36
16.09
1 month
15.3617.71
Current year
13.0217.71
1 year
12.8818.00
3 years
9.2018.00
5 years
9.2023.84
10 years
9.2041.32
| Managers | Title | Age | Since |
|---|---|---|---|
Jing Su
CEO | Chief Executive Officer | 61 | 18-04-15 |
Jie Wei
DFI | Director of Finance/CFO | 47 | 18-07-08 |
Ying Zhao
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiao Meng Jiang
BRD | Director/Board Member | 60 | 07-08-16 |
Ai Jian Wang
BRD | Director/Board Member | 70 | 21-06-01 |
Jin Yong Cai
BRD | Director/Board Member | 52 | 06-03-24 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.25% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-15 | 15.63 | +1.36% | 12,973,250 |
| 24-04-12 | 15.42 | -1.28% | 9,455,876 |
| 24-04-11 | 15.62 | -0.45% | 8,545,474 |
| 24-04-10 | 15.69 | -1.32% | 8,140,747 |
| 24-04-09 | 15.9 | +1.08% | 12,470,870 |
End-of-day quote Shanghai S.E., April 14, 2024
More quotes
Tasly Pharmaceutical Group Co Ltd is a China-based company principally engaged in the manufacture and distribution of pharmaceutical products. The Company's main businesses include the manufacture and sales of traditional Chinese medicines, chemical preparations, chemical raw materials and biological medicines. The Company's main products include Compound Danshen Dropping Pills, Yangxuenao Granules, Yangxuenao Pills, Qishen Yiqi Dropping Pills, Diqing and Shuilinjia. Its products are used to treat cardiovascular and cerebrovascular diseases, tumors, colds, fevers and liver diseases. The Company mainly distributes its products in the domestic market.
Sector
Pharmaceuticals
Calendar
2024-04-15
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
15.63
CNY
Average target price
14.92
CNY
Spread / Average Target
-4.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.17% | 3.17B | |
| +35.52% | 5.83B | |
| -14.82% | 4.53B | |
| -1.66% | 2.89B | |
| -2.70% | 2.52B | |
| +34.83% | 1.73B | |
| -11.67% | 1.62B | |
| -6.18% | 1.55B | |
| -12.74% | 1.54B | |
| -14.06% | 1.37B |
- Stock Market
- Equities
- 600535 Stock
